300 related articles for article (PubMed ID: 17225119)
1. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
2. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
3. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
5. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
[TBL] [Abstract][Full Text] [Related]
6. Radiolabelling DOTA-peptides with 68Ga.
Breeman WA; de Jong M; de Blois E; Bernard BF; Konijnenberg M; Krenning EP
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):478-85. PubMed ID: 15655678
[TBL] [Abstract][Full Text] [Related]
7. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
8. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
[TBL] [Abstract][Full Text] [Related]
9. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
10. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
[TBL] [Abstract][Full Text] [Related]
11. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
[TBL] [Abstract][Full Text] [Related]
12. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
14. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
Froidevaux S; Eberle AN; Christe M; Sumanovski L; Heppeler A; Schmitt JS; Eisenwiener K; Beglinger C; Mäcke HR
Int J Cancer; 2002 Apr; 98(6):930-7. PubMed ID: 11948475
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
[TBL] [Abstract][Full Text] [Related]
17. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount.
de Jong M; Breeman WA; Bernard BF; van Gameren A; de Bruin E; Bakker WH; van der Pluijm ME; Visser TJ; Mäcke HR; Krenning EP
Eur J Nucl Med; 1999 Jul; 26(7):693-8. PubMed ID: 10398816
[TBL] [Abstract][Full Text] [Related]
18. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
19. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
